PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-51.43%
Both yoy net incomes decline, with GNPX at -0.74%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
31.39%
Some D&A expansion while GNPX is negative at -2.76%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
0.95%
SBC growth while GNPX is negative at -21.68%. John Neff would see competitor possibly controlling share issuance more tightly.
2999.17%
Slight usage while GNPX is negative at -21.93%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
284.36%
A yoy AP increase while GNPX is negative at -303.61%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
139.25%
Growth well above GNPX's 166.80%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
3478.66%
Some yoy increase while GNPX is negative at -146.09%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
582.93%
Some CFO growth while GNPX is negative at -9.71%. John Neff would note a short-term liquidity lead over the competitor.
-3757.14%
Both yoy lines negative, with GNPX at -1086.75%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3757.14%
Both yoy lines negative, with GNPX at -311.73%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
-4.55%
We cut debt repayment yoy while GNPX is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.